Saturday, 31 October 2026European Markets

THUNDERBIRD Stock Went Up By Over 31% In The Last 21 Sessions

Loading stream...

Thunderbird Bird (AEX-Index: TBIRD.AS), a gaming, hospitality and real estate company made headlines as its stock saw an intense rise of 31.74% over 21 sessions. As of 17:09 on Friday afternoon, its stock price shot up from EUR0.08 to EUR0.11, following suit from its last winning session. However, in an intriguing contrast to Thunderbird Bird's good fortune, the AEX-Index fell by 1.63% to EUR765.14, breaking its two-day win streak.

Thunderbird Bird's Operations

Based in Panama, Thunderbird Bird operates in Nicaragua and Peru, boasting assets that include three slot parlors, three casinos, and 630 gaming positions. It also ventures into real estate development, where it specializes in owning and renting out office spaces.

Trading Volume Decline

Interestingly, despite the stocks soaring, the trading volume decreased, standing at 48,500 – a fall of 23.82% from its average volume of 63,665. This might be a sign that the dramatic increase in price is not backed by a comparable number of buyers, which could signal potential concerns about its value.

Earnings per Share and P/E Ratio

As per recent reports, Thunderbird Bird's trailing twelve months earnings per share (EPS) was at EUR0.01. In addition to this, the price-earnings ratio for the same period was 10.5, implying that an investor would have to shed EUR10.5 for each euro of annual earnings despite the recent price gains. A high P/E ratio like this might be an indicator that the stock is overpriced in comparison to its earnings.

Investor's Perspective

Investors need to pay close attention to such trends, thoroughly analyzing the situation before making any investment decisions. While rising stocks might seem enticing, investors must also evaluate trading volumes and P/E ratios to correctly gauge a stock's potential and true value.

More news about THUNDERBIRD (TBIRD.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com